FDA/CMS Device Trade Secret Memo Added To Regulatory Reform Wish List
This article was originally published in The Gray Sheet
Executive Summary
FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform
You may also be interested in...
QS Initiative Gains Significance In 2003 Budget Crunch – McClellan
FDA's quality systems improvement initiative is the vehicle by which Commissioner Mark McClellan hopes to leverage substantial device review reforms from CDRH's FY 2003 appropriation of $208 mil
QS Initiative Gains Significance In 2003 Budget Crunch – McClellan
FDA's quality systems improvement initiative is the vehicle by which Commissioner Mark McClellan hopes to leverage substantial device review reforms from CDRH's FY 2003 appropriation of $208 mil
BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year